Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hematoporphyrin Injection Photodynamic Therapy for Malignant and Precancerous Lesions of Cavities and Superficial Sites
ChiCTR-OIC-17011128Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2017
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hemoporfin in Non-hematologic malignancy and Premalignancy, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Adverse reactions. Started Mar 2017; status: recruiting.
02
Drugs
hemoporfin
03
Conditions
Non-hematologic malignancyPremalignancy
Beyond the preview
Go deeper on ChiCTR-OIC-17011128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011128.